ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2857

The Role Of FAM173b As a Newly Identified Regulator Of Chronic Pain

Hanneke Willemen1, Annemiek Kavelaars2, Rafael González Cano1,3, Cobi Heijnen2 and Niels Eijkelkamp4, 1NIDOD, UMC Utrecht, Utrecht, Netherlands, 2MD Anderson Cancer Center, Houston, TX, 3Department of pharmacology, University of Granada, Granada, Spain, 4Laboratory of Neuroimmunology and Developmental Origins of Disease (NIDOD), UMC Utrecht, Utrecht, Netherlands

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Chronic pain, inflammation and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of Pain in Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Chronic pain is a major debilitating problem in many inflammatory diseases including rheumatoid arthritis and osteoarthritis. Pain is an important problem during active disease but often continues during minimal disease activity or even after sustained remission. Chronic pain is often difficult to treat and new insights into the mechanisms underpinning the development of chronic pain are needed. Recently we have identified involvement of the 5p15.2 region that includes the coding region for CCT5 and FAM173b in chronic widespread pain (CWP). The minor allele frequency of two highly correlated SNPs (rs13361160 and rs2386592) annotated to the 5p15.2 region were associated with a 30% increased risk for CWP. 130 associated SNPs were identified that were in linkage disequilibrium with these two top SNPs and included one non-synonymous SNP (rs2438652) located in the coding region in the FAM173B gene. Here we examined the role of FAM173b in regulating chronic inflammatory pain.

Methods: FAM173b antisense oligonucleotides (asODN) were injected intrathecally to establish in vivo knockdown of FAM173b in sensory neurons. Transient inflammatory hyperalgesia was induced by intraplantar injection of a low dose of carrageenan in mice. Chronic inflammatory hyperalgesia was induced by intraplantar injection of Complete Freund Adjuvant (CFA). Development of hyperalgesia was assessed by using the Hargreaves’ method to determine heat sensitivity, while Von Frey hairs were used to assess mechanical sensitivity.

Results: FAM173b is upregulated in the lumbar spinal cord and dorsal root ganglion after peripheral inflammation induced by intraplantar CFA. Knockdown of FAM173b by intrathecal injection of FAM173b antisense oligodeoxynucleotides reduced the intensity of transient carrageenan-induced inflammatory thermal and mechanical hyperalgesia. Importantly, FAM173b knockdown during established chronic CFA-induced hyperalgesia completely attenuated CFA-induced persistent thermal and mechanical hyperalgesia. Mechanistically, intrathecal FAM173b asODN treatment completely prevented CFA-induced increase in Iba1+ microglia/macrophages with an activated phenotype in the spinal cord and DRG.  Moreover, FAM173b asODN treatment reduced spinal cord and DRG Iba1 mRNA expression. Intrathecal FAM173b asODN prevented CFA-induced upregulation of the pro-inflammatory cytokine TNF-a in the lumbar spinal cord and dorsal root ganglia. In contrast, FAM173b asODN did not affect CFA-induced increase in BDNF mRNA expression in the DRG.

Conclusion: We have identified an as yet unrecognized role for FAM173b in chronic inflammatory pain. We propose that FAM173b promotes spinal cord and DRG microglia/macrophages activation and subsequent pro-inflammatory cytokine production leading to persistent inflammatory pain.


Disclosure:

H. Willemen,
None;

A. Kavelaars,
None;

R. González Cano,
None;

C. Heijnen,
None;

N. Eijkelkamp,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-fam173b-as-a-newly-identified-regulator-of-chronic-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology